Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 2/2014

01-02-2014 | Research Article

MCAM expression is associated with poor prognosis in non-small cell lung cancer

Authors: X. Zhang, Z. Wang, Y. Kang, X. Li, X. Ma, L. Ma

Published in: Clinical and Translational Oncology | Issue 2/2014

Login to get access

Abstract

Background

MCAM has been recently identified as a biomarker for epithelial–mesenchymal transition (EMT) and is potentially involved in metastasis of cancer. The current study aimed at investigating the expression of MCAM in non-small-cell lung cancer (NSCLC) and its clinico-pathological significance.

Methods

A follow-up analysis was performed on 118 patients with NSCLC resected by lobectomy or pneumectomy with systematic lymph node dissection. All patients were followed for 6–60 months. Immunostaining of tissue sections from primary tumors and their lymph node metastasis was performed and evaluated using monoclonal antibody against MCAM, E-cadherin, and vimentin. Correlations were investigated between MCAM immunostaining in primary tumors and E-cadherin, vimentin immunostaining, lymph node metastasis, and survival.

Results

MCAM protein expression was found in 46.61 % of squamous cell carcinomas and 37.47 % of adenocarcinomas; MCAM expression positively correlated with vimentin, but inversely with E-cadherin (both P values <0.05). There were significant correlations between the MCAM immunostaining score in primary tumors and in their lymph node metastasis (P = 0.03). According to the Kaplan–Meier survival estimate, the level of MCAM expression in primary tumors was a statistically significant prognostic factor (P < 0.05).

Conclusions

MCAM expression in surgically treated NSCLC is clearly associated with lymph node metastasis and poor prognosis.
Literature
1.
2.
Ettinger DS, Akerley W, Borghaei H, Chang A, Cheney RT, Chirieac LR et al. NCCN Clinical Practice Guidelines in Oncology Non-small cell lung cancer Version 3. 2011. National comprehensive cancer network. http://​www.​nccn.​com (2011) Accessed 7 June 2011.
3.
Ou SH, Zell JA, Ziogas A, Anton-Culver H. Prognostic factors for survival of stage I non-small cell lung cancer patients: a population-based analysis of 19,702 stage I patients in the California cancer registry from 1989 to 2003. Cancer. 2007;110(7):1532–41.PubMedCrossRef
4.
Spira A, Ettinger DS. Multidisciplinary management of lung cancer. N Engl J Med. 2004;350(4):379–92.PubMedCrossRef
5.
Thiery JP. Epithelial–mesenchymal transition in tumor progression. Nat Rev Cancer. 2002;2(6):442–54.PubMedCrossRef
6.
Huber MA, Kraut N, Beug H. Molecular requirements for epithelial–mesenchymal transition during tumor progression. Curr Opin Cell Biol. 2005;17(5):548–58.PubMedCrossRef
7.
Lee JM, Dedhar S, Kalluri R, Thompson EW. The epithelial–mesenchymal transition: new insights in signaling, development, and disease. J Cell Biol. 2006;172(7):973–81.PubMedCrossRef
8.
9.
Sers C, Kirsch K, Rothbacher U, Riethmuller G, Johnson JP. Genomic organization of the melanoma-associated glycoprotein MUC18: implications for the evolution of the immunoglobulin domains. Proc Natl Acad Sci USA. 1993;90(18):8514–8.PubMedCrossRef
10.
Wang Z, Yan X. CD146, a multi-functional molecule beyond adhesion. Cancer Lett. 2013;330(2):150–62.PubMedCrossRef
11.
Bardin N, Anfosso F, Masse JM, Cramer E, Sabatier F, Le Bivic A, et al. Identification of CD146 as a component of the endothelial junction involved in the control of cell–cell cohesion. Blood. 2001;98(13):3677–84.PubMedCrossRef
12.
Shih IM, Speicher D, Hsu MY, Levine E, Herlyn M. Melanoma cell–cell interactions are mediated through heterophilic Mel-CAM/ligand adhesion. Cancer Res. 1997;57(17):3835–40.PubMed
13.
Wu GJ, Peng Q, Fu P, Wang SW, Chiang CF, Dillehay DL, et al. Ectopical expression of human MUC18 increases metastasis of human prostate cancer cells. Gene. 2004;327(2):201–13.PubMedCrossRef
14.
Aldovini D, Demichelis F, Doglioni C, Di Vizio D, Galligioni E, Brugnara S, et al. MCAM expression as marker of poor prognosis in epithelial ovarian cancer. Int J Cancer. 2006;119(8):1920–6.PubMedCrossRef
15.
Zabouo G, Imbert AM, Jacquemier J, Finetti P, Moreau T, Esterni B, et al. CD146 expression is associated with a poor prognosis in human breast tumors and with enhanced motility in breast cancer cell lines. Breast Cancer Res. 2009;11(1):R1.PubMedCentralPubMedCrossRef
16.
Bidlingmaier S, He J, Wang Y, An F, Feng J, Barbone D, et al. Identification of MCAM/CD146 as the target antigen of a human monoclonal antibody that recognizes both epithelioid and sarcomatoid types of mesothelioma. Cancer Res. 2009;69(4):1570–7.PubMedCentralPubMedCrossRef
17.
Wang W, Yang ZL, Liu JQ, Jiang S, Miao XY. Identification of CD146 expression, angiogenesis, and lymphangiogenesis as progression, metastasis, and poor-prognosis related markers for gallbladder adenocarcinoma. Tumor Biol. 2012;33(1):173–82.CrossRef
18.
Liu WF, Ji SR, Sun JJ, Zhang Y, Liu ZY, Liang AB, et al. CD146 expression correlates with epithelial–mesenchymal transition markers and a poor prognosis in gastric cancer. Int J Mol Sci. 2012;13(5):6399–406.PubMedCentralPubMedCrossRef
19.
Schlagbauer-Wadl H, Jansen B, Muller M, Polterauer P, Wolff K, Eichler HG, et al. Influence of MUC18/MCAM/CD146 expression on human melanoma growth and metastasis in SCID mice. Int J Cancer. 1999;81(6):951–5.PubMedCrossRef
20.
Zeng GF, Cai SX, Wu GJ. Up-regulation of METCAM/MUC18 promotes motility, invasion, and tumorigenesis of human breast cancer cells. BMC Cancer. 2011;11:113.PubMedCentralPubMedCrossRef
21.
Zeng Q, Li W, Lu D, Wu Z, Duan H, Luo Y, et al. CD146, an epithelial–mesenchymal transition inducer, is associated with triple-negative breast cancer. Proc Natl Acad Sci USA. 2012;109(4):1127–32.PubMedCrossRef
22.
Imbert AM, Garulli C, Choquet E, Koubi M, Aurrand-Lions M, Chabannon C. CD146 expression in human breast cancer cell lines induces phenotypic and functional changes observed in epithelial–mesenchymal transition. PLoS ONE. 2012;7(8):e43752.PubMedCentralPubMedCrossRef
23.
Kristiansen G, Yu Y, Schluns K, Sers C, Dietel M, Petesen I. Expression of the cell adhesion molecule CD146/MCAM in non-small cell lung cancer. Anal Cell Pathol. 2003;25:77–81.PubMed
24.
Oka S, Uramoto H, Chikaishi Y, Tanaka F. The expression of CD146 predicts a poor overall survival in patients with adenocarcinoma of the lung. Anticancer Res. 2012;32(3):861–4.PubMed
25.
Travis WD, Brambilla E, Mueller-Hermelink HK, Harris CC. World health organization classifications of tumors. Pathology and genetics of tumors of the lung, pleura, thymus and heart. 2nd ed. Lyon: IARC Press; 2004.
26.
Tischler V, Pfeifer M, Hausladen S, Schrimer U, Bonde AK, Kristiansen G, et al. L1CAM protein expression is associated with poor prognosis in non-small cell lung cancer. Mol Cancer. 2011;10:127.PubMedCentralPubMedCrossRef
27.
Wu Z, Wu Z, Li J, Yang X, Wang Y, Yu Y, et al. MCAM is a novel metastasis marker and regulates spreading, apoptosis and invasion of ovarian cancer cells. Tumour Biol. 2012;33(5):1619–28.PubMedCentralPubMedCrossRef
28.
29.
Zigler M, Villares GJ, Dobroff AS, Wang H, Huang L, Braeuer RR, et al. Expression of Id-1 is regulated by MCAM/MUC18: a missing link in melanoma progression. Cancer Res. 2011;71(10):3494–504.PubMedCentralPubMedCrossRef
30.
Zeng G, Cai S, Liu Y, Wu GJ. METCAM/MUC18 augments migration, invasion, and tumorigenicity of human breast cancer SK-BR-3 cells. Gene. 2012;492(1):229–38.PubMedCrossRef
31.
Chen W, Zhang HL, Jiang YG, Li JH, Liu BL, Sun MY. Inhibition of CD146 gene expression via RNA interference reduces in vitro perineural invasion on ACC-M cell. J Oral Pathol Med. 2009;38(2):198–205.PubMedCrossRef
32.
Leslie MC, Zhao YJ, Lachman LB, Hwu P, Wu GJ, Bar-Eli M. Immunization against MUC18/MCAM, a novel antigen that drives melanoma invasion and metastasis. Gene Ther. 2007;14(4):316–23.PubMedCrossRef
Metadata
Title
MCAM expression is associated with poor prognosis in non-small cell lung cancer
Authors
X. Zhang
Z. Wang
Y. Kang
X. Li
X. Ma
L. Ma
Publication date
01-02-2014
Publisher
Springer Milan
Published in
Clinical and Translational Oncology / Issue 2/2014
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-013-1057-6

Other articles of this Issue 2/2014

Clinical and Translational Oncology 2/2014 Go to the issue

Research Article

Selecting housekeeping genes as references for the normalization of quantitative PCR data in breast cancer

Research Article

What is the future burden of HPV-related cancers in Spain?

Educational Series - Red Series

Renal cell carcinoma in pregnancy: a rare coexistence

Correspondence

Tackling gliomas with nanoformulated antineoplastic drugs: suitability of hyaluronic acid nanoparticles

Research Article

Proteomic analysis of pleural effusion from lung adenocarcinoma patients by shotgun strategy

Research Article

PKM2 and ACVR 1C are prognostic markers for poor prognosis of gallbladder cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits